RTN2 Antibody

What is RTN2 and why is it significant in neurological research?

RTN2 (Reticulon 2) belongs to the family of reticulon proteins that primarily localize to the endoplasmic reticulum (ER). RTN2 plays crucial roles in shaping the tubular ER network, membrane trafficking, and inhibition of axonal growth . Its significance in neurological research stems from its association with hereditary spastic paraplegia (SPG12) and distal hereditary motor neuropathy (dHMN) . RTN2 also participates in a network of hairpin loop-containing ER morphogens that includes REEP1, atlastin-1, and M1 spastin, making it a critical target for studying ER morphogenesis and axonal degeneration mechanisms .

What are the main applications for RTN2 antibodies in experimental research?

RTN2 antibodies are primarily used in the following experimental applications:

The choice of application depends on the research question, with WB being useful for protein expression quantification, IHC for localization studies, and IP for investigating protein-protein interactions such as those between RTN2 and other ER-resident proteins .

How should RTN2 antibodies be stored and handled to maintain optimal activity?

For maximum stability and activity, RTN2 antibodies should be stored at -20°C, where they remain stable for approximately one year after shipment . The standard storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . While aliquoting is unnecessary for -20°C storage of smaller (20μl) sizes that contain 0.1% BSA, it is recommended for larger volumes to prevent repeated freeze-thaw cycles. Before use, allow the antibody to equilibrate to room temperature and mix gently to ensure homogeneity. Avoid vortexing, which can damage the antibody structure .

What are the optimal protocols for using RTN2 antibodies in Western blotting of neuronal samples?

When performing Western blotting with RTN2 antibodies on neuronal samples:

• Sample preparation: Extract proteins from skeletal muscle tissue or neuronal cultures using RIPA buffer supplemented with protease inhibitors.

• Expected band size: While calculated molecular weights for RTN2 isoforms are 59 kDa, 51 kDa, and 22 kDa, the observed molecular weight typically ranges from 20-23 kDa .

• Loading control selection: For neuronal samples, β-tubulin III serves as an appropriate loading control as it's specifically expressed in neurons and helps distinguish neuronal expression from glial expression .

• Optimization steps:

  • Use a dilution series (1:500, 1:1000, 1:2000) to determine optimal antibody concentration

  • Include positive controls such as mouse or human skeletal muscle tissue, where RTN2 is highly expressed

  • For detection of specific isoforms, note that the long isoform (RTN2B, 52 kDa) is present in brain and spinal cord, whereas the short isoform (18 kDa) is expressed in skeletal muscle and heart

• Troubleshooting low signal: When signal is weak, extend primary antibody incubation to overnight at 4°C and use enhanced chemiluminescence detection systems with increased exposure times .

How can I validate the specificity of RTN2 antibodies in my experimental system?

Rigorous validation of RTN2 antibodies ensures experimental reliability through multiple complementary approaches:

• Positive and negative tissue controls: Use skeletal muscle tissue as a positive control, as it consistently shows high RTN2 expression. Non-neuronal tissues generally express lower levels and can serve as comparative controls .

• Genetic validation approaches:

  • siRNA knockdown: Utilize RTN2-specific siRNAs in primary neuronal cultures, which should result in a significant reduction of RTN2 staining intensity (to approximately 22-26% relative to untransfected cells)

  • Knockout models: If available, tissues from RTN2 knockout models provide the most definitive negative control

• Isoform specificity testing: To distinguish between RTN2 isoforms, use antibodies targeting unique regions. For instance, an antibody against the NH2 terminus of RTN2B specifically recognizes the 52-kDa long isoform .

• Cross-reactivity assessment: Test against other reticulon family members (RTN1, RTN3, RTN4) to ensure specificity, as these proteins share homology in the reticulon homology domain (RHD) .

• Immunoprecipitation-mass spectrometry: For ultimate confirmation, perform IP with the RTN2 antibody followed by mass spectrometry to identify all captured proteins .

What are the recommended approaches for immunohistochemical detection of RTN2 in tissue samples?

For optimal immunohistochemical detection of RTN2:

• Tissue preparation:

  • For FFPE samples: Use 4-6 μm sections mounted on positively charged slides

  • For frozen sections: Fix with 4% paraformaldehyde prior to antibody incubation

• Antigen retrieval methods:

  • Primary recommendation: TE buffer at pH 9.0

  • Alternative method: Citrate buffer at pH 6.0

• Antibody dilution range: Start with 1:20-1:200 dilution and optimize based on tissue type

• Detection systems:

  • For fluorescence: Use appropriate secondary antibodies conjugated to fluorophores

  • For chromogenic detection: HRP-DAB systems provide good contrast for RTN2 visualization in skeletal muscle tissue

• Counterstaining: For co-localization studies with neuronal markers, β-tubulin III is recommended as it specifically marks neurons and helps distinguish RTN2 neuronal expression from glial expression

• Interpretation guidance: RTN2B staining in neurons should be distributed throughout the cell body and neurites, consistent with ER localization. In cells strongly expressing RTN2, punctate structures may be observed .

How can RTN2 antibodies be utilized to study protein-protein interactions in ER morphogenesis?

RTN2 antibodies are valuable tools for investigating protein-protein interactions involving RTN2 in ER morphogenesis through several advanced approaches:

• Co-immunoprecipitation strategy:

  • Use anti-RTN2 antibodies to pull down RTN2 and its binding partners from neuronal lysates

  • Western blot analysis can then identify interaction partners such as GTRAP3-18, EAAC1, and M1 spastin

  • When performing RTN2 co-IP, extraction buffers should contain mild detergents (0.5-1% NP-40 or Triton X-100) to preserve membrane protein interactions

• Proximity ligation assays (PLA):

  • This technique can visualize RTN2 interactions with other proteins in situ

  • Combine RTN2 antibodies with antibodies against potential binding partners (e.g., IP3R for Ca2+ signaling studies or M1 spastin for ER-shaping studies)

  • PLA signals indicate proteins are within 40 nm proximity, supporting direct interaction

• FRET microscopy applications:

  • For live-cell studies, combine immunofluorescence using RTN2 antibodies with fluorescently tagged binding partners

  • This approach is particularly useful for validating dynamic interactions identified in co-IP experiments

• Domain mapping considerations:

  • Use RTN2 antibodies against specific domains to determine which regions participate in protein interactions

  • For example, the transmembrane domains of RTN2B have been identified as important for GTRAP3-18 binding

These methods have revealed that RTN2B interacts with GTRAP3-18 and EAAC1 independently, and that these interactions occur through different domains of RTN2B, with the first transmembrane domain being crucial for GTRAP3-18 binding .

What are the challenges in discriminating between RTN2 isoforms using antibodies?

Discriminating between RTN2 isoforms presents several technical challenges that researchers should address with specific strategies:

• Isoform-specific epitope targeting:

  • RTN2 has multiple isoforms including the long brain-specific isoform (RTN2B, 52 kDa) and shorter isoforms expressed in muscle (18-23 kDa)

  • Select antibodies raised against unique N-terminal regions to discriminate between isoforms

  • Antibodies targeting the C-terminal region will detect all isoforms as this region contains the conserved reticulon homology domain (RHD)

• Resolving similar molecular weight isoforms:

  • Use high-percentage (12-15%) SDS-PAGE gels with extended run times for better separation

  • Consider using Phos-tag™ acrylamide gels if phosphorylation differences between isoforms exist

• Validation approach for isoform specificity:

  Isoform	Tissue Expression	Expected MW	Validation Method
  RTN2B (long)	Brain, spinal cord	52 kDa	RT-PCR with isoform-specific primers; isoform-specific siRNA
  RTN2A/C (short)	Skeletal muscle, heart	18-23 kDa	Tissue-specific controls; isoform-specific siRNA

• Common troubleshooting for multiple bands:

  • Extra bands at approximately double the expected molecular weight may represent dimers of RTN2 proteins, as RTNs can form homo-oligomers

  • Post-translational modifications may alter migration patterns

  • Validate with recombinant proteins expressing specific isoforms

• Technical recommendation: When studying neuron-specific functions, use the chicken antibody raised against residues 30-48 on the NH2 terminus of RTN2B, which specifically recognizes the 52-kDa RTN2B isoform expressed in neurons .

How do RTN2 antibodies perform in detecting pathogenic variants associated with neurological disorders?

RTN2 antibodies show varying efficacy in detecting pathogenic variants associated with neurological disorders, requiring careful consideration of several factors:

• Detection of truncated variants:

  • The frameshift mutation R60fs (associated with SPG12) produces a severely truncated protein lacking the RHD

  • Standard C-terminal-targeting antibodies fail to detect this variant, necessitating N-terminal-specific antibodies

  • Experimental validation: When expressed in HEK293 cells, truncated RTN2 shows diffuse cytosolic and nuclear localization rather than ER localization

• Missense variants detection challenges:

  • Point mutations like S367F (S294F in RTN2B) maintain protein expression but alter function

  • While antibodies can detect these variants, they cannot distinguish them from wild-type proteins without specialized approaches

  • Functional validation through subcellular localization studies is required to complement antibody detection

• Loss-of-function variant analysis:

  • For recently identified homozygous loss-of-function RTN2 variants causing distal hereditary motor neuropathy

  • Antibody staining intensity can be used to confirm reduced expression at the protein level

  • Western blotting of patient fibroblasts can quantify the extent of protein loss

• Methodological guidance for variant studies:

  • Combine antibody detection with genetic analysis and functional studies

  • For heterozygous carriers, quantitative Western blotting may reveal ~50% reduction in protein levels

  • For missense mutations, co-immunoprecipitation assays can assess impact on protein-protein interactions

• Research application examples: RTN2 antibodies have been successfully used to confirm the presence of mutated transcripts in patient blood lymphocytes through RT-PCR followed by protein detection, demonstrating that these transcripts escape nonsense-mediated mRNA decay .

How can RTN2 antibodies contribute to understanding ER calcium regulation in neurodegenerative disorders?

RTN2 antibodies provide valuable insights into ER calcium regulation in neurodegenerative disorders through several experimental approaches:

• Co-localization studies with calcium regulators:

  • RTN2 antibodies can be used in combination with antibodies against IP3R (inositol trisphosphate receptor) to study their interaction

  • This interaction has been demonstrated to facilitate Ca2+ release from the ER, with implications for neuronal function

  • Immunofluorescence co-localization can map these interactions in different neuronal compartments

• Calcium imaging in RTN2-manipulated systems:

  • RTN2 antibodies can validate knockdown or overexpression models before calcium imaging experiments

  • Following confirmation of altered RTN2 expression, calcium indicators can measure the functional impact on ER calcium stores and release dynamics

• Therapeutic intervention assessment:

  • Recent research in C. elegans models of RTN2 deficiency showed that treatment with 2,5-di-tert-butylhydroquinone (DTBHQ), an ER/SR Ca2+ reuptake inhibitor, rescued key phenotypic differences

  • RTN2 antibodies can confirm the molecular consequences of such interventions in mammalian systems

• Methodological approach for calcium regulation studies:

  • Combine RTN2 immunoprecipitation with IP3R antibodies to isolate the RTN2-IP3R complex

  • Use antibodies against phosphorylated ERK to monitor downstream signaling activation

  • Western blot analysis following calcium chelation treatments can establish causality between calcium dysregulation and altered RTN2 function

• Research application in different disease models: RTN2 antibodies have demonstrated that RTN2 can interact with IP3R and influence calcium signaling, suggesting potential therapeutic targets for both motor neuron disorders and certain cancers where RTN2 expression is dysregulated .

What is the role of RTN2 antibodies in cancer research, particularly regarding metastasis mechanisms?

RTN2 antibodies are increasingly valuable in cancer research, particularly for investigating metastatic mechanisms, as evidenced by recent discoveries:

• Expression profiling in tumor tissues:

  • Immunohistochemistry with RTN2 antibodies has revealed upregulated RTN2 expression in gastric cancer tissues compared to pericarcinomatous tissues

  • Quantifiable staining intensity correlates with clinicopathological features including vessel invasion, tumor invasion depth, lymph node metastasis, and TNM stage

• Prognostic marker validation:

  • Tissue microarray analysis using RTN2 antibodies has established RTN2 as an independent prognostic factor for gastric cancer patients

  • High RTN2 staining intensity associates with adverse survival outcomes

  • Combining RTN2 staining with TNM staging improves predictive accuracy

• Mechanistic studies in cancer progression:

  • RTN2 antibodies enable investigation of downstream pathways activated by RTN2

  • Western blotting with phospho-specific antibodies reveals RTN2's role in activating ERK signaling via facilitation of Ca2+ release from the ER

  • This mechanistic pathway drives epithelial-to-mesenchymal transition (EMT) in cancer cells

• Experimental design for metastasis studies:

  Experimental Approach	Application of RTN2 Antibodies	Key Findings
  In vitro migration/invasion assays	Validation of RTN2 knockdown/overexpression	RTN2 promotes cellular migration and invasion
  In vivo metastasis models	Confirmation of RTN2 expression in metastatic lesions	RTN2 enhances lung metastasis in animal models
  Co-IP experiments	Detection of RTN2-IP3R interaction	RTN2 interacts with IP3R to facilitate calcium release

• Translational research implications: RTN2 antibodies have helped identify RTN2 as a potential molecular target for cancer therapies, particularly for aggressive forms with metastatic potential .

How do I resolve contradictory findings when using different RTN2 antibodies in my research?

When confronted with contradictory results using different RTN2 antibodies, systematic troubleshooting is essential:

• Epitope mapping analysis:

  • Different antibodies target distinct regions of RTN2

  • Antibodies against the N-terminus may detect only specific isoforms (e.g., RTN2B)

  • C-terminal antibodies typically detect all isoforms but may miss truncated disease-associated variants

  • Create an epitope map of each antibody used and correlate with potential protein domains or isoform-specific regions

• Cross-reactivity assessment:

  • Test against other reticulon family members (RTN1, RTN3, RTN4)

  • The reticulon homology domain (RHD) is highly conserved, increasing cross-reactivity risk

  • Perform validation in tissues from knockout models or after siRNA knockdown

• Validation with complementary techniques:

  Technique	Purpose	Approach
  RNA analysis	Confirm transcript presence	RT-PCR with isoform-specific primers
  Mass spectrometry	Identify actual proteins	IP followed by MS analysis
  Recombinant protein controls	Establish antibody specificity	Test with purified proteins of known sequence
  Genetic knockdown	Validate signal specificity	siRNA targeting different regions of RTN2

• Context-dependent expression considerations:

  • RTN2 expression varies dramatically by tissue: long isoform (RTN2B) in brain and spinal cord; short isoform in skeletal muscle and heart

  • Cell type-specific expression: RTN2B is neuron-specific, not present in astrocytes

  • Developmental stage may affect isoform expression patterns

• Technical optimization recommendations:

  • For neuronal studies, prioritize chicken antibodies against RTN2B NH2 terminus (residues 30-48)

  • For studies of disease-associated variants, use antibodies targeting regions preserved in the variant

  • When studying complex tissues, consider cell type-specific markers for co-localization

  • Always report the specific antibody, catalog number, and dilution used to enable replication

What emerging technologies are enhancing the specificity and sensitivity of RTN2 antibody applications?

Several cutting-edge technologies are improving RTN2 antibody applications:

• Single-cell proteomics integration:

  • Combining RTN2 antibodies with single-cell mass cytometry (CyTOF) allows simultaneous detection of RTN2 with dozens of other proteins at single-cell resolution

  • This enables more precise characterization of RTN2 expression patterns in heterogeneous neural populations

• Super-resolution microscopy applications:

  • Given RTN2's role in ER morphogenesis, super-resolution techniques provide unprecedented visualization of RTN2 distribution

  • STORM or PALM microscopy with RTN2 antibodies can resolve structures below the diffraction limit, revealing detailed organization of RTN2 at ER tubule junctions and contact sites

• Proximity-dependent biotinylation:

  • BioID or APEX2 fusion to RTN2 followed by antibody-based validation identifies proximal proteins in living cells

  • This approach has revealed novel interaction partners beyond those identified by traditional co-immunoprecipitation

• CRISPR-engineered endogenous tagging:

  • Knock-in of small epitope tags to endogenous RTN2 allows antibody detection while maintaining physiological expression levels

  • This circumvents overexpression artifacts sometimes observed with traditional antibody approaches

• Automated high-content screening platforms:

  • Combinatorial antibody-based screening in disease models facilitates discovery of compounds that normalize RTN2 function

  • Recent proof-of-concept: DTBHQ was identified as a compound that rescues RTN2 deficiency phenotypes in C. elegans models

These emerging technologies are expanding the utility of RTN2 antibodies beyond traditional applications, enabling more sophisticated investigations into RTN2 function in both normal physiology and disease states.

How can I integrate RTN2 antibody-based research with genetic models to understand neurodegenerative mechanisms?

Integrating RTN2 antibody-based research with genetic models offers powerful insights into neurodegenerative mechanisms:

• Complementary validation strategy:

  • Use RTN2 antibodies to confirm protein changes in genetic models (knockouts, knockdowns, or disease-specific mutations)

  • Verify behavioral or cellular phenotypes correlate with altered RTN2 expression or localization

  • Example: In C. elegans models with loss-of-function of the RTN2 ortholog ret-1, antibody validation can confirm complete protein loss before phenotypic analysis

• Functional rescue experiments:

  • In RTN2-deficient models, reintroduce wild-type or mutant RTN2 and use antibodies to:

    • Confirm expression levels match physiological levels

    • Verify correct subcellular localization

    • Evaluate restoration of protein-protein interactions

  • This approach can determine which RTN2 functions are essential for preventing neurodegeneration

• Cross-species validation approach:

  Model System	Antibody Application	Insight Gained
  C. elegans ret-1 mutants	Verification of ortholog function	Behavioral phenotypes rescued by DTBHQ
  Patient-derived fibroblasts	Detection of RTN2 expression/localization	No significant alterations in ER structure
  Mouse models	Tissue-specific expression analysis	Isoform distribution differences
  Human post-mortem tissues	Pathological changes in disease states	Correlation with disease progression

• Time-course analysis in degenerative models:

  • Use RTN2 antibodies to track changes in expression or localization throughout disease progression

  • Correlate molecular changes with onset of pathological hallmarks

  • Determine whether RTN2 alterations precede or follow other disease markers

• Therapeutic target validation:

  • Compounds like DTBHQ that modify calcium reuptake can rescue RTN2 deficiency phenotypes

  • Use RTN2 antibodies to determine if therapeutic interventions restore normal protein interactions or localization

  • This approach has successfully identified potential therapeutic strategies for RTN2-associated motor neuropathies

By systematically integrating antibody-based detection with genetic models, researchers can establish causality between RTN2 dysfunction and neurodegenerative processes while identifying potential intervention points.